Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy

British Journal of Cancer

Volumn 103, Issue 9, 2010, Pages 1318-1324

  Bernhard, J ^a,b   Dietrich, D ^a   Glimelius, B ^c   Hess, V ^d   Bodoky, G ^e   Scheithauer, W ^f   Herrmann, R ^d  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Szent Laszlo Hospital   (Hungary)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

advanced pancreatic carcinoma; CA 19 9 tumour marker; palliation; prognostic factor; quality of life

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77958553912     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605929     Document Type: Article

References (24)

1. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi BC,Kohne C-H, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Herrmann R (2008) Clinical benefit and quality of life in patients withadvanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized Multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN. 1.3.001. J Clin Oncol 26: 3695-3701
2. Bernhard J, Hurny C, Maibach R, Herrmann R, Laffer U (1999) Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 10: 775-782
3. Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM (2001) Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84: 1156-1165
4. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16: 282-288
5. Butow P, Coates A, Dunn S, Bernhard J, Hurny C (1991) On the receiving end. IV: validation of quality of life indicators. Ann Oncol 2: 597-603
6. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J (2006) Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17: 1698-1704
7. Fang FM, Liu YT, Tang Y, Wang CJ, Ko SF (2004) Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 100: 425-432
8. Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM (1987) The memorial pain assessment card. A valid instrument for the evaluation of cancer pain. Cancer 60: 1151-1158
9. Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26: 1355-1363
10. Gupta D, Lis CG, Grutsch JF (2006) The European organization for research and treatment of cancer quality of life questionnaire: implications for prognosis in pancreatic cancer. Int J Gastrointest Cancer 37: 65-73
11. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212-2217
12. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreaticcancer enrolled in a randomised controlled trial. Lancet Oncol 9: 132-138
13. Hurny C, Bernhard J, Bacchi M, van Wegberg B, Tomamichel M, Spek U, Coates A, Castiglione M, Goldhirsch A, Senn HJ (1993) The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1: 200-208
14. Hurny C, Bernhard J, Coates A, Peterson HF, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Goldhirsch A, Senn HJ (1996) Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 34: 234-248
15. La'ulu SL, Roberts WL (2007). Performance characteristics of five automated CA 19-9 assays. Am J Clin Pathol 127: 436-440.
16. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93: 740-743
17. Micke O, Bruns F, Kurowski R, Horst E, deVries AF, Hausler JW, Willich N, Schafer U (2003) Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 57: 90-97
18. Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health and Quality of Life Outcomes 7: 102
19. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10: 865-871
20. Robinson Jr DW, Eisenberg DF, Cella D, Zhao N, de Boer C, DeWitte M (2008) The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol 6: 283-290
21. Sloan JA, Dueck A (2004) Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 14: 73-96
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
23. Van Steen K, Curran D, Kramer J, Molenberghs G, Van Vreckem A, Bottomley A, Sylvester R (2002) Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med 21: 3865-3884
24. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psychooncology 10: 19-28